New drug shows promise against tough cancers

NCT ID NCT05119907

Ongoing Disease control Sponsor: Gilead Sciences Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests a drug called sacituzumab govitecan in 53 adults with advanced solid tumors that have not responded to standard treatments. The main goal is to see if the drug can shrink tumors. Researchers will also track how long any response lasts and how well the drug controls the disease.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BILIARY TRACT CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

biliary tract cancer cervical cancer esophageal squamous cell carcinoma gastric adenocarcinoma lung adenocarcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

SOLID TUMOR

Contacts and locations

Locations

Anhui Provincial Hospital

Hefei, 230001, China
Beijing Cancer Hospital

Beijing, 100142, China
Beijing Obstetrics and Gynecology Hospital, Capital Medical University

Beijing, 100006, China
Chinese Academy of Medical Sciences Cancer Hospital

Beijing, 100021, China
Fujian Cancer Hospital

Fuzhou, 350014, China
Harbin Medical University Cancer Hospital

Harbin, 150076, China
Henan Cancer Hospital

Zhengzhou, 450000, China
Jiangsu Province Hospital

Nanjing, 210029, China
The First Affiliated Hospital, Zhejiang University School of Medicine

Hangzhou, 310003, China
The First Hospital of Jilin University

Changchun, 130021, China
The Sixth Affiliated Hospital, Sun Yat-Sen University

Guangzhou, 510655, China
Union Hospital Tongji Medical College Huazhong University of Science and Technology

Wuhan, 43006, China
Zhejiang Cancer Hospital

Hangzhou, 310022, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.